Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Mimedx (MDXG) Cash from Discontinued Operations (2023 - 2024)

Mimedx's Cash from Discontinued Operations history spans 2 years, with the latest figure at 1000.0 for Q4 2024.

On a quarterly basis, Cash from Discontinued Operations fell 99.9% to 1000.0 in Q4 2024 year-over-year; TTM through Sep 2025 was 1000.0, a 98.21% decrease, with the full-year FY2024 number at 930000.0, up 88.61% from a year prior.
Cash from Discontinued Operations hit 1000.0 in Q4 2024 for Mimedx, up from 1000.0 in the prior quarter.
Over the last five years, Cash from Discontinued Operations for MDXG hit a ceiling of 987000.0 in Q4 2023 and a floor of 4648000.0 in Q1 2023.